Research programme: B-cell isolation platform therapeutics - Adimab

Drug Profile

Research programme: B-cell isolation platform therapeutics - Adimab

Alternative Names: ADI 15742; ADI 15878; Anti-Ebola virus antibodies - Adimab; Anti-RSV antibodies

Latest Information Update: 16 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adimab
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Respiratory syncytial virus infections

Highest Development Phases

  • Preclinical Ebola virus infections
  • Research Respiratory syncytial virus infections

Most Recent Events

  • 09 Dec 2016 Research programme: B-cell isolation platform therapeutics - Adimab is available for licensing as of 09 Dec 2016. http://www.adimab.com/
  • 18 Feb 2016 Early research in Respiratory syncytial virus infections in USA (Parenteral) before February 2016
  • 18 Feb 2016 Preclinical trials in Ebola virus infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top